The future of combination therapies in I-O: insights, challenges, & future endeavors

Immuno-Oncology Insights 2024; 5(1), 1–6

DOI: 10.18609/ioi.2024.001

Published: 10 January
Roy Baynes

Lauren Coyle, Editor of Immuno-Oncology Insights, interviews Roy Baynes, Executive Vice President and Chief Medical Officer of Eikon Therapeutics (pictured), about the development strategy of combination therapies, specifically in early-stage disease, in the I-O space.